ClinicalTrials.gg
RecruitingNCT04615065AcutelinesUpdated Jun 13, 2024

Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine

An observational study in Acute Disease, Sepsis and Pneumonia, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by University Medical Center Groningen · Observational

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35,000
Ages
18 Years and older
Sex
All
01

Study summary

Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care. To overcome some of these challenges, the Center of Acute Care of the University Medical Center Groningen in the Netherlands, has established a de novo data-, image- and biobank named "Acutelines". Acutelines is initiated to improve recognition and treatment of acute diseases and obtain insight in the consequences of acute diseases, including factors predicting its outcome. Thereby, Acutelines contributes to development of personalized treatment and improves prediction of patient outcomes after an acute admission.

Read the detailed description

Acutelines is a prospective biobank including patients with a broad spectrum of acute conditions. Its aim is to facilitate interdisciplinary research on the etiology and development of acute diseases with the aid of systematically collected biomaterials and medical data over various timepoints, both during the course of the patient's disease and after recovery. Clinical data, imaging data and biomaterial (i.e. blood, urine, feces, hair) are collected for patients presenting to the Emergency Department (ED) with a broad range of acute disease presentations. A deferred consent procedure (by proxy), is in place to allow collecting data and biomaterials prior to obtaining written consent. The digital infrastructure in place and the software used ensures automated capturing of all bed-side monitoring data (i.e. electrophysiological waveforms, vital parameters), and the secure importation of data from other sources, such as the electronic health records of the hospital, ambulance and general practitioner, municipal registration, health insurance companies and pharmacy. Follow up data are collected for all included patients during the first 72-hours of their hospitalization and 3-months, 1-year, 2-years and 5 years after their ED visit.

Data and materials to be collected includes:

  • Demographic and health data (i.e. [experiences] health, quality of life, functional status)
  • Medical history (i.e. co-morbidity, intoxications, medication use)
  • Admission reason to emergency department
  • Physical examination and vital parameters
  • Clinical diagnostic data (i.e. [point-of-care] ultrasound, X-ray, CT-scan, laboratory results)
  • Electrophysiological waveforms (i.e. electrocardiogram [ECG], plethysmography)
  • Biomaterials
  • Treatment (i.e. medication use, non-pharmacological treatment, treatment decisions, length-of-stay in hospital, admission to intensive care unit [ICU])
02

Conditions studied

  • Acute Disease
  • Sepsis
  • Pneumonia
  • Frailty
  • Complication of Treatment
  • Pulmonary Embolism
  • Thrombosis
  • Acute Kidney Injury
  • Electrolyte Disturbance
  • Hemorrhage
  • Shock
  • Polypharmacy
  • Intoxication by Drug
  • Emergencies
  • Urinary Tract Infections
  • Skin Infection
  • Syncope
  • Anaphylaxis
  • Dyspnea

Keywords

  • Acute disease
  • Sepsis
  • Emergency Medical Service (EMS)
  • Outcome
  • Precision medicine
  • Personalized medicine
  • Emergency medicine
  • Multidisciplinary
  • General practitionar
  • Pharmacy
  • Hospitalization
  • Health insurance
  • Mortality
  • Quality of life (QoL)
  • Overcrowding
  • Patient logistics
  • Point-of-care ultrasound (POCUS)
  • Helicopter Emergency Medical Service (HEMS)
  • Biobank
  • Databank
  • Electrophysiological waveforms
  • Electrocardiogram (ECG)
  • Plethysmogram
03

In context

Acute Disease

57 studies on the registry are indexed under Acute Disease; 12 are open to participants now.

This study's planned enrollment of 35,000 is above the median of 900 across 22 observational studies indexed under Acute Disease.

Browse Acute Disease studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 176 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients admitted to the emergency room for emergency medicine, internal medicine [including sub-specializations as allergology, acute medicine, oncology, hematology, infectiology, nephrology, vascular medicine, geriatric medicine], pulmonology, gastro-enterology and rheumatology.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Triaged as one of highest two triage categories (red or orange) according to the Manchester triage system;
  • Triaged as the third highest triage category (yellow) and arrival by EMS of Helicopter Emergency Medical Service (HEMS;
  • Shock
  • Suspicion of sepsis (based on either physicians' suspicion, Sepsis-2 or Sepsis-3 criteria)
  • Acute kidney injury (AKI)
  • Anaphylactic reaction
  • Syncope
  • Intoxication
  • Thrombosis
  • Pulmonary embolism
  • Bleeding while using anti-coagulant drugs
  • Gastro-intestinal bleeding
  • Electrolyte disturbance

Exclusion criteria

Exclusion Criteria:

  • Referred for organ transplantation as recipient
  • Transfer from other hospital
  • Accidental contact patient material (i.e. internal work-related accident)

While data- and imaging will be collected from all these patients, biomaterials will only be collected from patients fulfilling the first criterion (i.e. triaged as one of highest two triage categories [red or orange] according to the Manchester triage system) and from patients with shock or a suspicion of sepsis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Mortality (time and cause)

    Mortality will be retrieved from the electronic health records (EHR) from the hospital and municipal registration. The cause of death will be retrieved from the EHR from the hospital, general practitioner and Dutch statistics' office (CBS).

    Time frame: Until the death of death from any cause, up to 50 years

  2. Katz ADL-6 (functioning)

    Katz ADL-6 (0-6, fully dependent-independent)

    Time frame: Up to 1 year

  3. World Health Organization (WHO) performance status (functioning)

    World Health Organization (WHO) performance status (0-4, normal performance-bedridden)

    Time frame: Up to 1 year

  4. Karnofsky performance score (functioning)

    Karnofsky performance score (10-100, moribund-normal performance)

    Time frame: Up to 1 year

  5. Utrecht Activity List (daily activities)

    Utrecht Activity List (UAL; hours/week spend on (a) paid work, (b) education, (c) household, (d) running errands, (e) unpaid work, (f) sport, (g) hobbies, (h) other use of leisure time )

    Time frame: Up to 1 year

  6. Short QUestionnaire to ASsess Health-enhancing physical activity (daily activities)

    Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH; minutes/week and intensity of activity spend (a) commuting, (b) at work, (c) household activities and (d) leisure time; increased score corresponds with increased physical activity)

    Time frame: Up to 1 year

  7. Quality of Life and experienced symptoms

    EuroQol-5D (EQ5D; simple descriptive profile and a single index value for health status; higher values corresponding with better health) with visual analogue scale (VAS; 0-100, worse-best experienced health)

    Time frame: Up to 1 year

  8. Experienced somatic symptoms

    Patient Health Questionnaire-15 (PHQ-15; 0-30, minimal-high somatic symptom severity)

    Time frame: Up to 1 year

  9. Fatigue

    Piper Fatigue Scale-12 (PFS-12; 0-10, higher scores reflect more fatigue among four subscales (a) behavior, (b) affect, (c) sensory, (d) cognition)

    Time frame: Up to 1 year

  10. Patient Health Questionnaire-2 (mental health)

    Patient Health Questionnaire-2 (PHQ-2; 0-6, higher score corresponds to reduced mental health)

    Time frame: Up to 1 year

  11. Patient Health Questionnaire-9 (mental health)

    Patient Health Questionnaire-9 (PHQ-9; 0-4 no depressive symptoms, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately severe depressive symptoms, 20-27 severe depressive symptoms)

    Time frame: Up to 1 year

  12. Geriatric Depression scale-15 (mental health)

    Geriatric Depression scale-15 (GDS-15; 0-4 no depressive symptoms, 5-10 mild depressive symptoms, 11-15 depressive symptoms)

    Time frame: Up to 1 year

  13. Patient satisfaction

    Patient Satisfaction Questionnaire Short-form (PSQ-18; measuring general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience; scored per domain, with lower scores corresponding with higher satisfaction)

    Time frame: Up to 1 year

  14. Decision making

    Outcome prioritization tool (OPT; 0-100% per domain of prioritization for (a) life extension, (b) preserving independence, (c) reducing pain and (d) reducing other symptoms)

    Time frame: Up to 1 year

  15. Co-morbidity

    Co-morbidity will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy. Data will be registered according to the Charlson' co-morbidity index (CCI; 1-2 mild co-morbidity, 3-4 moderate co-morbidity, 5 severe co-morbidity)

    Time frame: Up to 5 years

  16. Length-of-stay in hospital/intensive care unit (ICU)

    Length-of-stay in hospital and on intensive care unit (ICU) in days

    Time frame: Until hospital discharge, an average of 2 weeks

Secondary outcomes

  1. Biomarkers

    Laboratory values (Hb \[mmol/L\], leukocytes \[/mL), trombocytes \[/ml\], creatinine \[mmol/L\], urea \[mmol/L\], CRP \[mg/L\], LDL cholesterol \[mmol/L\], HDL cholesterol \[mmol/L\], total cholesterol \[mmol/L\], AST \[U/L\], ALT \[U/L\], gGT \[U/L\], AF \[U/L\], bilirubin \[microl/L\], NTproBNP \[pg/mL\], troponin \[microg/L\]) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy.

    Time frame: Up to 5 years

  2. Medication use

    Medication use will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and pharmacy.

    Time frame: Up to 5 years

  3. Treatment (non-pharmacological, including organ support)

    Treatment (non-pharmacological) will be retrieved from the electronic health records (EHR) from the hospital, general practitioner and (helicopter) emergency medical service. Data will include intravenous fluid resuscitation, vasopressors, mechanical ventilation/non-invasive ventilation, oxygen supply, acute dialysis and extra-corporeal membrane oxygenation (ECMO)

    Time frame: Until hospital discharge, up to 3 months

  4. Sequential organ failure assessment (SOFA)

    SOFA scores will be available for patients admitted because of an infection.

    Time frame: Up to 72 hours after hospitalization

  5. Vital parameters

    Heart rate (bpm), blood pressure (mmHg), oxygen saturation (SpO2, SaO2, PaO2), breathing frequency (per min), consciousness (Glasgow coma scale), pain score (VAS), nausea/vomiting (y/n), defecation (y/n), urination (y/n), body weight (kg), length (cm), fluid balance (ml/day).

    Time frame: Until hospital discharge, up to 3 months

07

Study locations

1 of 1 sites recruiting
  • University Medical Center Groningen
    Groningen, 9700 RB, Netherlands
    Recruiting
    • Hjalmar Bouma, MD, PhD · Contactacutelines@umcg.nl · 0503616161
    • Hjalmar Bouma, MD, PhD · Principal investigator
    • Ewoud ter Avest, MD, PhD · Sub investigator
    • Jan ter Maaten, MD, PhD · Sub investigator
08

References and documents

Publications

  • Ter Avest E, van Munster BC, van Wijk RJ, Tent S, Ter Horst S, Hu TT, van Heijst LE, van der Veer FS, van Beuningen FE, Ter Maaten JC, Bouma HR. Cohort profile of Acutelines: a large data/biobank of acute and emergency medicine. BMJ Open. 2021 Jul 15;11(7):e047349. doi: 10.1136/bmjopen-2020-047349. PubMed 34266842 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) may be available to other researchers if needed for their specific research purposes, which amongst others must be in line with the study protocol, the informed consent form and the general data protection regulations (GDPR). Each request for re-use of data will be reviewed by Acutelines' steering group, manager and local review board (LRb), prior to establishing a material and data transfer agreement (MDTA). No IPD will be shared if not required to answer research question.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Supporting information will become available short after initiation of the study and will remain available until the end of the study (undetermined).

Access criteria: Supporting information will either be made available through the website (http://acutelines.umcg.nl), LinkedIn (https://www.linkedin.com/company/acutelines) and/or upon reasonable request.

Data sharing details ↗ · acutelines.umcg.nl

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04615065
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Sep 1, 2020
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Jun 13, 2024

Study contacts

Hjalmar Bouma, MD, PhD
Contact
acutelines@umcg.nl
+31 50 361 6161
Ewoud ter Avest, MD, PhD
study chair · University Medical Center Groningen
Jan ter Maaten, MD, PhD
study director · University Medical Center Groningen
Hjalmar Bouma, MD, PhD
study director · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion